{{Rsnum
|rsid=1056892
|Gene=CBR3
|Chromosome=21
|position=36146408
|Orientation=plus
|GMAF=0.3838
|Gene_s=CBR3,CBR3-AS1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 13.3 | 36.3 | 50.4
| HCB | 15.3 | 44.5 | 40.1
| JPT | 13.3 | 47.8 | 38.9
| YRI | 24.7 | 51.4 | 24.0
| ASW | 17.5 | 52.6 | 29.8
| CHB | 15.3 | 44.5 | 40.1
| CHD | 15.9 | 46.7 | 37.4
| GIH | 29.7 | 47.5 | 22.8
| LWK | 23.9 | 39.4 | 36.7
| MEX | 1.7 | 50.0 | 48.3
| MKK | 11.7 | 47.4 | 40.9
| TSI | 16.7 | 52.0 | 31.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1056892
|Name_s=CBR3 V244M
|Gene_s=CBR3
|Feature=
|Evidence=PubMed ID:18457324
|Annotation=Risk or phenotype-associated allele: G. Phenotype: There was a trend toward an association between the CBR3 V244M polymorphism and the risk of CHF. Study size: 145. Study population/ethnicity: Nested case-control study was conducted within a cohort of 1979 patients enrolled in the Childhood Cancer Survivor Study who received treatment with anthracyclines and had available DNA. Significance metric(s): OR = 8.16, p = 0.056 (G/G vs A/A); OR = 5.44, p = 0.092 (G/A vs A/A). Type of association: CO; TOX; ADR.
|Drugs=
|Drug Classes=ANTHRACYCLINES AND RELATED SUBSTANCES
|Diseases=Cardiomyopathies; Drug Toxicity; Heart Failure
|Curation Level=Curated
|PharmGKB Accession ID=PA165291869
}}

{{PharmGKB
|RSID=rs1056892
|Name_s=CBR3 730G>A; CBR3:Val244Met
|Gene_s=CBR3
|Feature=
|Evidence=PubMed ID:18551042
|Annotation=Risk or phenotype-associated allele: A. Phenotype: CBR3 730G>A was associated with higher doxorubicinol AUC and CBR3 expression in breast tumor tissue. Study size: 101 Study population/ethnicity: Asian; patients with Breast Neoplasms; Chinese; Malay; Indian Significance metric(s): p = 0.009 (AUC); p = 0.001 (expression) Type of association: PK; TOX
|Drugs=doxorubicin
|Drug Classes=ANTHRACYCLINES AND RELATED SUBSTANCES
|Diseases=Breast Neoplasms; Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165291532
}}

{{GET Evidence
|gene=CBR3
|aa_change=Val244Met
|aa_change_short=V244M
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1056892
|overall_frequency_n=4307
|overall_frequency_d=10758
|overall_frequency=0.400353
|n_genomes=32
|n_genomes_annotated=0
|n_haplomes=41
|n_articles=2
|n_articles_annotated=2
|in_pharmgkb=Y
|pph2_score=0.014
|nblosum100=0
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}